Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Receivables (2016 - 2021)

Vistagen Therapeutics (VTGN) has disclosed Receivables for 4 consecutive years, with $81200.0 as the latest value for Q1 2021.

  • Quarterly Receivables changed N/A to $81200.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $81200.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $81200.0 for FY2021, N/A changed from the prior year.
  • Receivables hit $81200.0 in Q1 2021 for Vistagen Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $81200.0 in Q1 2021 to a low of $81200.0 in Q1 2021.